The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease.
Chronic hepatitis B patients with fatty liver disease are gradually increasing. We aim to investigate the serum fragment level of cytokeratin 18 (CK-18), M30 and M65, in chronic hepatitis B (CHB) patients with and non-alcoholic fatty liver disease (NAFLD). Serum M30 and M65 levels were measured by ELISA assay in 46 CHB patients with NAFLD and 42 CHB patients without NAFLD. The association of serum M30 levels in 46 CHB patients with NAFLD and biochemistry and pathological indexes were investigated. The serum M30 levels in CHB with NAFLD group were 614.48 ± 471.43 U/L, which were significantly higher than non NAFLD group (374.50 ± 231.04 U/L, p < 0.01). But there were no differences in serum M65 levels between NAFLD group (369.41 ± 262.21 U/L) and non-NAFLD group (296.50 ± 231.44 U/L, p = 0.172). We observed significantly higher serum M30 levels in CHB with NAFLD patients with positive HBV-DNA (752.36 ± 554.79 U/L) as compared with patients with negative HBV-DNA (400.0 ± 171.64 U/L, p < 0.05). While the M65 levels have no significant difference (p = 0.285). For CHB patient with NAFLD patients, the M30 level was positively correlated with ALT, AST, HBVDNA, TG, FBG, histology inflammation score, fibrosis score and steatosis (p < 0.01). Serum M30 levels in CHB with NAFLD patients are significantly higher than CHB patients without NAFLD, especially for HBV-DNA positive patients. It could be a reference value for evaluating the inflammation degree of CHB with NAFLD.